Create knowledge
[?]
|
(rate this)
|
Today clinical research industry has achieved growth from Rs. 20 crores to Rs. 100 crores. Clinical research, Clinical trial, Clinical data, clinical content management are all inter-related field and fall under the scope of biotechnology, microbiology, biochemistry and genetics. Mother subjects like biotechnology, microbiology biotechnology is no more restricted to petriplates, pipettes, conical flask and chemicals-which is know as ‘wet lab systems’. It has expanded its wings to ‘dry labs system’. The dry labs basically emphasizes on -Sequence analysis, drug toxicity, pharmacokinetics studies, market analysis, biometrics (statistical analysis), regulatory affairs of new drugs, which in turn...
Insight: "The clinical data management Hub" deleted from your view.
|
(rate this)
|
|
Yes
|
2
|
VS |
5
|
No
|
 |
SHASHANK SHEODE
| Argues in support of
"No"
| 1 year ago
|
|
No this ban will not effect as many Pharma companies in india have started giving quality drugs as compared to few years back.New policies and overall changes in the industry there will be no effect of ban on indian companies.There are many...
|
|
|
|
Arpit Mishra
| Argues in support of
"Yes"
| 3 years ago
|
|
The US action is bound to have adverse repercussions in regulated markets such as Europe, Japan, Australia, New Zealand and other markets of Asia, Africa and Latin America where Ranbaxy markets its formulations. Naturally these countries will...
|
|
 |
Anand G Badve
| Argues in support of
"No"
| 2 years ago
|
|
yes they are following the norms but not india .When India will do this
|
|
Debate: "Will US ban on ranbaxy drugs will effect other Indian Pharma companies? " deleted from your view.
Follow me on
